Thymosin α1 Explored for Immune Support in Rheumatic Heart Disease Surgery

Patients suffering from rheumatic heart disease (RHD) often present with compromised immune function, making them particularly vulnerable. The complex process of cardiac surgery involving cardiopulmonary bypass (CPB) further intensifies this immune suppression, significantly increasing the risk of postoperative complications. Consequently, preventing this severe decline in immune function after surgery is a critical, unmet clinical need, and immunomodulatory therapies like Thymosin α1 (Tα1) are being investigated for their potential benefits.

This abstract outlines the design and hypothesis of an ongoing clinical trial, rather than presenting completed results or specific efficacy data. Therefore, quantitative findings on immune function improvements or patient prognosis are not yet available. The researchers hypothesize that the administration of Thymosin α1 will lead to a significant improvement in various immune markers and clinical outcomes when compared to the control group. > The central aim of this study is to determine if Thymosin α1 can effectively mitigate the profound immune suppression induced by cardiopulmonary bypass in rheumatic heart disease patients. Expected outcomes, pending the study's completion, include enhanced immune cell counts, improved cytokine profiles, and a potential reduction in the incidence of postoperative infections or complications.